Instead, it could increase the risk of side effects like nausea, headache, or digestive issues
Semaglutide 2.4 mg (Wegovy): ~15% body weight loss at 68 weeks in clinical trials Tirzepatide 15 mg (Zepbound): ~21% body weight loss at 72 weeks in clinical trials Real-world data shows lower results: Cleveland Clinic research from 2025 found average weight loss of 7.7% with semaglutide and 12.4% with tirzepatide at one year in routine clinical practice
GLP-1 Maintenance Is Not One Decision Patients often ask, Do I have to stay on GLP-1 medication forever? The better answer is that maintenance is not one decision
If necessary, adjustments to medication doses or additional treatments are made to ensure that each patients weight loss plan is as effective and sustainable as possible
Learn more on our Idaho telehealth page
In many cases, an in-person evaluation is required to initiate therapy